Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer.

Title:: Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer.
Document type:: Journal Article; Review
Author(s):: Ettl, Johannes
Abstract:: Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed.
Journal title abbreviation:: Breast Care (Basel)
Year:: 2016
Journal volume:: 11
Journal issue:: 3
Pages contribution:: 174-6
Language:: eng
Fulltext / DOI:: doi:10.1159/000447417
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/27493616
Print-ISSN:: 1661-3791
TUM Institution:: Frauenklinik und Poliklinik
BibTeX

Occurrences: